You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences Files $500 Million Shelf Registration Statement
Gilead Sciences Announces Completion of Redemption of 5% Convertible Subordinated Notes
Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B
Gilead Sciences Calls for Redemption of Convertible Subordinated Notes
Cauley Geller Announces Class Action Lawsuit Against Gilead Sciences, Inc. On Behalf of Investors
Shareholder Class Action Filed Against Gilead Sciences, Inc. by the Law Firm of Schiffrin & Barroway, LLP
Milberg Weiss Announces the Filing of a Class Action Suit against Gilead Sciences, Inc. on Behalf of Investors
Gilead Sciences to Present at Credit Suisse First Boston 2003 Healthcare Conference; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at Credit Suisse First Boston 2003 Healthcare Conference
Gilead Sciences Amends Stockholder Rights Plan
Gilead Sciences Announces Third Quarter 2003 Financial Results
Gilead Sciences' HIV Drug Emtriva Approved for Marketing in European Union
New Data Highlight Safety and Tolerability Profile of Gilead's Viread for Periods up to Four Years; Data Presented at European AIDS Conference in Warsaw
Gilead Announces 144-Week Data of Hepsera in Patients Co-Infected With HIV And Lamivudine-Resistant HBV
Gilead Sciences to Release Third Quarter Financial Results on Tuesday, October 28, 2003; Conference Call and Webcast to Follow
Mark Perry Joins Nuvelo Board of Directors
IntraBiotics Names Mark L. Perry to Its Board of Directors
Gilead Sciences to Present Corporate Update at the UBS Global Life Sciences Conference on Tuesday, September 23, 2003
Gilead Purchases Foster City Campus
Gilead Signs Agreement to Acquire Foster City Campus
Gilead Initiates Study 934, a 48-Week Clinical Trial Evaluating Viread and Emtriva versus Combivir
Gilead and Chiron Corporation Sign Non-Exclusive HCV Licensing Agreement; Gilead to Initiate Research Programs in Hepatitis C
Gilead Sciences Announces Second Quarter 2003 Financial Results
Gilead and Japan Tobacco Sign Licensing Agreement for Commercialization of Gilead's HIV Products in Japan
Gilead Sciences to Release Second Quarter Financial Results on Thursday, July 31, 2003; Conference Call and Webcast to Follow
European CPMP Gives Positive Opinion on Emtriva, Gilead's New Once-Daily Treatment for HIV
Phase III Trial of Emtriva, New Once-Daily Capsule for HIV, Shows Continued Response Through 60 Weeks
Gilead Sciences Expects Second Quarter 2003 Financial Results Will Exceed Expectations; Increase Driven Primarily by Higher Viread Revenues
Gilead Sciences Announces Selling Securityholder Registration Statement Declared Effective by SEC
U.S. FDA Approves Gilead Sciences' Emtriva, a One-Capsule, Once-Daily Medication for the Treatment of HIV
Gilead and Bukwang End Licensing Agreement for Clevudine, Investigational Agent for Chronic Hepatitis B
96-Week Data from Gilead's Study 903 Show Low Rate of Virologic Failure among Patients Taking Viread
Gilead Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Healthcare Conference; Webcast Available through Gilead Corporate Website
European Commission Expands the Indication of Viread, Gilead's Once-Daily Treatment for HIV, to Include Treatment-Naive Patients
Gilead Launches Web Site for Hepsera, Its Chronic Hepatitis B Drug
Gilead Sciences Announces First Quarter 2003 Financial Results; Record Viread Sales of $107 Million; Product Sales of $156 Million, Up 121 Percent over First Quarter 2002
Gilead Sciences to Release First Quarter Financial Results on Wednesday, April 23, 2003; Conference Call and Webcast to Follow
96-Week Data Show Hepsera Reduces Liver Damage and Improves Liver Function in More Than 70 Percent of Patients with Hepatitis B ``E'' Antigen-Negative Disease
Gilead Launches Access Program to Provide Anti-HIV Therapy Viread in 68 Developing Countries at No Profit
Gilead Sciences' Hepatitis B Drug Hepsera Approved for Marketing in European Union
Results of Two Pivotal Studies of Gilead's Hepsera Published in the New England Journal of Medicine
European CPMP Gives Positive Opinion to Extend the Indication of Viread, Gilead's Once-Daily Treatment for HIV Infection
Phase III Data Show Emtricitabine Maintains Viral Load Suppression as Part of Once-Daily, Protease-Sparing Anti-HIV Regimen
96-Week Data From Phase III Study Show Long-Term Efficacy With Reduced Risk of Lipid and Metabolic Changes for Viread Versus Stavudine in Treatment-Naive HIV Patients
Gilead Sciences Announces Fourth Quarter and Full Year 2002 Financial Results; Full Year Product Sales of $424 Million, Up 122 Percent over 2001; Net Income of $72 Million for 2002
Gilead Sciences to Release Fourth Quarter and Year-End 2002 Financial Results on Thursday, January 30, 2003; Conference Call and Webcast to Follow
Gilead Sciences Completes Acquisition of Triangle Pharmaceuticals
Gilead Sciences Successfully Completes Tender Offer for Shares of Triangle Pharmaceuticals with 97 Percent of Shares Tendered
2012 Interactive Annual Report